Home/Filings/4/0000899243-18-024270
4//SEC Filing

FINCK BARBARA K 4

Accession 0000899243-18-024270

CIK 0001512762other

Filed

Sep 11, 8:00 PM ET

Accepted

Sep 12, 4:05 PM ET

Size

9.3 KB

Accession

0000899243-18-024270

Insider Transaction Report

Form 4
Period: 2018-09-10
FINCK BARBARA K
Chief Medical Officer
Transactions
  • Sale

    Common Stock, $0.0001 par value

    2018-09-10$18.58/sh1,760$32,69937,043 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2018-09-101,76082,941 total
    Exercise: $1.42Exp: 2023-11-21Common Stock (1,760 underlying)
  • Exercise/Conversion

    Common Stock, $0.0001 par value

    2018-09-10$1.42/sh+1,760$2,49938,803 total
Footnotes (3)
  • [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
  • [F2]The transaction was executed in multiple trades in prices ranging from $18.20 to $19.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F3]The shares underlying this option are fully vested and exercisable as of the date hereof.

Issuer

Coherus BioSciences, Inc.

CIK 0001512762

Entity typeother

Related Parties

1
  • filerCIK 0001242116

Filing Metadata

Form type
4
Filed
Sep 11, 8:00 PM ET
Accepted
Sep 12, 4:05 PM ET
Size
9.3 KB